Details

Autor(en) / Beteiligte

• Bordeau, Karl
• Michalet, Morgan
• Keskes, Aïcha
• Valdenaire, Simon
• Debuire, Pierre
• Cantaloube, Marie
• Cabaillé, Morgane
• Jacot, William
• Draghici, Roxana
• Demontoy, Sylvain
• Quantin, Xavier
• Ychou, Marc
• Assenat, Eric
• Mazard, Thibault
• Gauthier, Ludovic
• Dupuy, Marie
• Guiu, Boris
• Bourgier, Céline
• Aillères, Norbert
• Fenoglietto, Pascal
• Azria, David
• Riou, Olivier

Titel

Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study

Ist Teil von

• Journal of clinical medicine, 2023-02, Vol.12 (3), p.1183

Ort / Verlag

Switzerland: MDPI

Erscheinungsjahr

2023

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Liver stereotactic body radiotherapy (SBRT) is a local treatment that provides good local control and low toxicity. We present the first clinical results from our prospective registry of stereotactic MR-guided radiotherapy (MRgRT) for liver metastases. All patients treated for liver metastases were included in this prospective registry study. Stereotactic MRgRT indication was confirmed by multidisciplinary specialized tumor boards. The primary endpoints were acute and late toxicities. The secondary endpoints were survival outcomes (local control, overall survival (OS), disease-free survival, intrahepatic relapse-free survival). Twenty-six consecutive patients were treated for thirty-one liver metastases between October 2019 and April 2022. The median prescribed dose was 50 Gy (40-60) in 5 fractions. No severe acute MRgRT-related toxicity was noted. Acute and late gastrointestinal and liver toxicities were low and mostly unrelated to MRgRT. Only 5 lesions (16.1%) required daily adaptation because of the proximity of organs at risk (OAR). With a median follow-up time of 17.3 months since MRgRT completion, the median OS, 1-year OS and 2-year OS rates were 21.7 months, 83.1% (95% CI: 55.3-94.4%) and 41.6% (95% CI: 13.5-68.1%), respectively, from MRgRT completion. The local control at 6 months, 1 year and 2 years was 90.9% (95% CI: 68.3-97.7%). To our knowledge, we report the largest series of stereotactic MRgRT for liver metastases. The treatment was well-tolerated and achieved a high LC rate. Distant relapse remains a challenge in this population.